Loading stock data…
$1.49-0.06 (-3.87%)
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States.
GRI Bio, Inc. in the Healthcare sector is trading at $1.49 with a market capitalization of $4M. Wall Street consensus targets $18.50 (2 analysts), implying a +1141.6% move over the next 12 months. The stock is currently near its 52-week low of $1.36, remaining 42.5% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 16 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$1.65M↑ | -$2.00M↑ | -$2.66M↑ | -$3.37M↓ | -$2.90M |
| Net Income | -$1.64M↑ | -$2.00M↑ | -$2.66M↑ | -$3.36M↓ | -$2.89M |
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candi...